Shattuck Labs (STTK)
(Delayed Data from NSDQ)
$9.43 USD
-0.15 (-1.57%)
Updated Apr 22, 2024 11:56 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STTK 9.43 -0.15(-1.57%)
Will STTK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STTK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STTK
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates
STTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
Amgen (AMGN) Q2 Earnings and Revenues Top Estimates
Other News for STTK
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
Analysts Conflicted on These Healthcare Names: Shattuck Labs (STTK), Johnson & Johnson (JNJ) and Tilray (TLRY)
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Strong Buy Rating for Shattuck Labs on Innovative Immunotherapy Pipeline and Leadership
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference